Del Rosso James Q, Tanghetti Emil, Webster Guy, Stein Gold Linda, Thiboutot Diane, Gallo Richard L
Dr. Del Rosso is Adjunct Clinical Professor of Dermatology at Touro University, Nevada in Henderson, Nevada; and Research Director at JDR Dermatology Research, Clinical Dermatology, Thomas Dermatology in Las Vegas, Nevada.
Dr. Tanghetti is with the Center for Dermatology and Laser Surgery in Sacramento, California.
J Clin Aesthet Dermatol. 2020 Jun;13(6 Suppl):S17-S24. Epub 2020 Jun 1.
Previous consensus articles on rosacea from the American Acne and Rosacea Society (AARS) have focused on pathophysiology, clinical assessment based on phenotypic expressions of rosacea, management guidelines, discussions of individual medical therapies, and reviews of physical modalities. Pathophysiologic mechanisms believed to be operative in rosacea have been covered extensively in the literature. This article updates the previously published consensus recommendations from the AARS on the management of rosacea, including systematic literature and evidence-based reviews of available therapeutic agents and physical modalities. This article includes discussions of available published data on topical ivermectin, topical oxymetazoline, combination therapy approaches, and physical devices for the management of rosacea. Consistent with what many publications on rosacea currently emphasize, clinicians are encouraged to define the clinical manifestations present in the patient and to select therapies that correlate with the optimal treatment of those manifestations. There are less data available on how to optimally integrate therapies; however, it appears that rationally selected medical therapies can be utilized concurrently. Due to the multifactorial pathogenesis of rosacea, its clinical presentation is heterogeneous. Rosacea is a chronic and recurrent inflammatory disorder, and clinical manifestations often vary in nature and severity over time, which might necessitate an adjustment in treatment. As new data become available, rosacea management approaches should be updated.
美国痤疮与酒渣鼻协会（AARS）此前发表的关于酒渣鼻的共识文章主要聚焦于病理生理学、基于酒渣鼻表型表达的临床评估、管理指南、个体药物治疗的讨论以及物理治疗方法的综述。文献中已广泛涵盖了被认为在酒渣鼻发病过程中起作用的病理生理机制。本文更新了AARS此前发布的关于酒渣鼻管理的共识建议，包括对现有治疗药物和物理治疗方法的系统文献及循证综述。本文讨论了关于外用伊维菌素、外用羟甲唑啉、联合治疗方法以及用于酒渣鼻管理的物理设备的已发表数据。与当前许多关于酒渣鼻的出版物所强调的一致，鼓励临床医生明确患者存在的临床表现，并选择与这些表现的最佳治疗相关的疗法。关于如何最佳地整合治疗方法的数据较少；然而，似乎可以同时合理选用医学治疗方法。由于酒渣鼻的发病机制具有多因素性，其临床表现具有异质性。酒渣鼻是一种慢性复发性炎症性疾病，临床表现常常随时间在性质和严重程度上有所不同，这可能需要调整治疗方案。随着新数据的出现，酒渣鼻的管理方法应不断更新。
